Director Ra Capital Management, L.P. buys $6.6 million of Bambusa Therapeutics, Inc. (BBTX)

Ra Capital Management, L.P., director of Bambusa Therapeutics, Inc., bought 453,820 shares on the open market on October 30, 2026 at an average of $14.63 a share, for a total of $6.6 million. The purchase was reported to the SEC on Form 4 on November 3, 2026.

It is a new position: the filing shows no shares held directly before this purchase.

2 other insiders also bought at least $10,000 of BBTX within 30 days, which makes this a cluster buy.

It is Ra Capital Management, L.P.'s first purchase of BBTX in at least 1 year of our records.

In the 12 months up to this filing, Bambusa Therapeutics, Inc. insiders reported 4 open-market purchases and 0 sales.

WallStPal Score: 70 out of 100, because of a brand-new position; a large purchase; first purchase in 1+ year; 2 other insiders also bought.

It is too soon to say how the stock did afterward. This page will update as prices come in.

Our read

It is one of 4 insider purchases at BBTX in the past year. A single purchase is a data point, not a forecast: insiders can be early, and sometimes simply wrong.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

We have no earlier insider purchases of Bambusa Therapeutics, Inc. with a measured result to compare against, so this purchase is the first data point. Our study of 2026 insider purchases found the typical purchase roughly kept pace with the S&P 500 over three months, with a minority doing much better.

Explain it like I'm 13

Ra Capital Management, L.P. helps run Bambusa Therapeutics, Inc.. Spending $6.6 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all BBTX insider trades · Ra Capital Management, L.P.'s track record